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a reﬂection of FSW clients’ preferences
for unprotected sex. These ﬁndings have
several important implications for HIV
prevention strategies among FSW. First,
the size of risky sex premium is large
enough that it may dampen the effec-
tiveness of certain behavioral interven-
tions to reduce STI and HIV risk among
FSW, such as condom promotion
efforts. Although condom promotion
efforts have had much success among
FSW7 and a large proportion of FSW in
our study also reported consistent con-
dom use, the large risk premiums in
combination with factors such as pov-
erty may contribute to some FSW
engaging in unprotected sex with clients.
Second, cash transfers conditioned on
avoiding STIs may serve as a way to
directly address the implications of the
risky sex premium, although the feasibil-
ity and scalability of such interventions
need to be assessed. Third, biomedical
interventions such as pre-exposure pro-
phylaxis may be a promising strategy to
reduce HIV infections among FSW
because price premiums for unprotected
sex are so large.
Comparing the size of the risky sex
premium in our study setting to those
estimated in other settings can be instruc-
tive. Estimates of premium vary widely in
the literature, from a 23% premium in
Mexico,8 a 66%–79% price reduction for
sex with condom in India,9 350% pre-
mium in the Demographic Republic of
Congo,10 and a 43% premium in rural
Zimbabwe.11 Another study in a different
part of western Kenya has shown that
formal and informal FSWs increased their
supply of unprotected sex when coping
with unexpected income shocks but found
considerably smaller risk premium of
only 9.3%.12 The large premiums in our
study setting could be due to the higher
HIV prevalence in Kisumu, as disease
risk is known to be an inﬂuential factor in
determining the size of risky sex premi-
ums.13 Consistent with ﬁndings from
other studies, more educated women were
able to negotiate higher prices overall and
a larger premium for unprotected sex than
less educated women.8,9,11 Education
might enable women to negotiate prices
that better compensate them for taking the
extra risk of unprotected sex.
Limitations of this study include
a small sample size of FSW who report
prices of sex without condoms and the
conduct of the study at only 1 site. We
explored whether FSW who did not
disclose a price for sex without con-
dom differed from the rest of the
sample but did not detect any differ-
ences in measured characteristics other
than whether they always used a con-
dom with clients. Additional data col-
lection from a larger sample and across
multiple sites can help assess the
generalizability of the results and
improve our understanding of the
commercial sex market. Nonetheless,
the consistency of our ﬁndings with
other studies provides greater conﬁ-
dence in their validity.
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Performance of Risk
Charts to Guide
TargetedHIV Viral Load
Monitoring of ART:
Applying the Method
on the Data From
a Multicenter Study in
Rural Lesotho
To the Editors:
We read the article of Koller et al1
on risk charts to guide targeted viral load
(VL) monitoring with great interest.
Although the World Health Organiza-
tion (WHO) guidelines on the use of
antiretroviral therapy (ART) published
in 2013 recommend routine VL moni-
toring, its implementation remains slow
in most countries in Sub-Saharan
N. D. Labhardt received a grant from Swiss
Foundation for Excellence and Talent in Bio-
medical Research, and a travel-grant through
Gilead. The remaining authors have no funding
or conﬂicts of interest to disclose.
Letters to the Editor J Acquir Immune Defic Syndr  Volume 72, Number 1, May 1, 2016
e22 | www.jaids.com Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
Copyright  2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Africa.2,3 In settings with limited labo-
ratory capacity for VL monitoring, tools
that help to identify the group of patients
who most need VL testing may provide
an alternative until HIV programs are
capacitated to implement routine VL
monitoring. Ideally such tools help to
sort out patients who are highly likely to
have virologic failure and those who are
very unlikely to fail, narrowing down
the number of patients receiving VL to
those who are at intermediate risk. WHO
immunological and clinical criteria per-
form poorly in predicting as well as
excluding virologic failure.4 Scores
based on clinical and laboratory param-
eters for identifying those who need
targeted VL had acceptable accuracy in
some settings,5,6 but not in others.7
Based on the analysis of 7 South
African cohorts including more than
30,000 patients, Koller et al propose
the use of risk charts based on basic
pieces of information: sex, time on
ART, baseline, and current CD4 counts.
The charts allow one to exclude patients
with very high or very low probability of
virologic failure, restricting VL testing
only to those with intermediate proba-
bility of failure. In a setting where
limited resources are available, the
charts help to optimize VL testing to
those patients with the highest uncer-
tainty on virologic outcome (10%, 20%,
or 40% of a cohort, depending on the
VL tests available).
Here we report performance of the
risk charts published by Koller et al on
data that had been collected as part of
a prospective study on virologic out-
comes and comorbidities in 10 rural
clinics in Lesotho, Southern Africa
[Comorbidities and Virologic Outcome
Among Patients on Anti-retroviral Ther-
apy in Rural Lesotho (CART)-1 www.
clinicalTrials.gov ID: NCT02126696].
Between May 5, 2014 and June 17,
2014, we assessed VL in patients on
ﬁrst-line ART $6 months in 10 clinics
located in 2 rural districts of Lesotho.
The study has been described in more
detail elsewhere.7
Patients with a plasma VL $1000
copies per milliliter can resuppress
spontaneously or after increased treat-
ment adherence.8 To avoid unnecessary
switching to a second-line regimen,
WHO therefore recommends a second
VL measurement after 3 months of
enhanced adherence support and switch
to second line if second VL remains
$1000 copies per milliliter.2,8 In accor-
dance with these guidelines, our study
measured a ﬁrst VL in all participants
with a follow-up VL 3 months later for
those with an elevated ﬁrst VL. Follow-
ing the method of Koller et al, we
assessed performance of the risk charts
in predicting single virologic failure
(ﬁrst VL $1000 copies per milliliter)
and sustained virologic failure (ﬁrst
and follow-up VL $1000 copies per
milliliter), as a function of time on ART,
CD4 at baseline, current CD4, and sex.
The statistical analysis used 2
methods:
• Method 1: we straightforwardly
applied the boundaries for CD4-cell
values deﬁned in Figure 1 of the
article of Koller et al.1 This method
implies that the percentage of patients
qualifying for VL testing may differ
from cohort to cohort and deviate
from the targeted values (10%, 20%,
or 40%).
• Method 2: we focused on the targeted
values of proportions of patients who
shall receive VL testing (10%, 20%,
or 40%). To achieve this objective, we
took the values from the central line in
Figure 1 from Koller et al and then
increased or decreased progressively
the interval widths till the targeted
proportion of the patients qualifying
for VL testing in our cohort
was reached.
Koller et al elaborated the risk
charts for patients on ART ,5 years.
Because approximately one-third of our
study population had been on ART $5
years, we assessed in an additional
analysis the robustness of the method
including patients on ART .5 years,
applying the boundary values at year 5.
To retrieve the lines plotted in
Figure 1 of Koller et al, we took 10
points of measurement and then pro-
ceeded with linear interpolation. All
TABLE 1. Measures of performance of Methods 1 and 2.
n = 905 0% VL Testing 10% VL Testing 20% VL Testing 40% VL Testing
Virologic Failure* Single Sustained Single Sustained Single Sustained Single Sustained
Method 1
n VL test (%) 0 58 (6.4) 113 (12.5) 222 (24.5)
PPV† 42 28 67 46 81 54 89 62
NPV‡ 96 97 97 98 97 98 97 98
Sensitivity 33 32 47 49 54 54 60 62
Speciﬁcity 97 96 98 98 99 98 99 98
Method 2
n VL test (%) 0 92 (10.2) 183 (20.2) 365 (40.3)
PPV 42 28 78 53 94 64 100 67
NPV 96 97 97 98 97 98 98 99
Sensitivity 33 32 51 51 56 57 71 70
Speciﬁcity 97 96 99 98 100 99 100 99
*Single virologic failure: ﬁrst VL $1000 copies per milliliter; sustained virologic failure: ﬁrst and follow-up VL $1000 copies per milliter.
†Positive predictive value.
‡Negative predictive value.
NPV, negative predictive value.
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analyses were run on R 3.2.2 (the R
Foundation for Statistical Computing),
and TIBCO Spotﬁre S+ 8.1 for Win-
dows (TIBCO Software Inc).
Among 1563 adults on ﬁrst-line
ART $6 months enrolled in the study,
1404 had both documented baseline and
current CD4 values. There were 69%
women, the median age was 44 years
(interquartile range 35–54), and the
median CD4 count at start of ART was
215 cells per cubic millimeter (inter-
quartile range 122–306). Among them,
905 (64%) had been on ART 6 months
to 5 years, the remaining 499 patients
had been on ART .5 years.
Results are shown in Table 1.
Applying method 1, using ﬁxed CD4-
value boundaries, fewer patients quali-
ﬁed for VL testing than in the article of
Koller et al (6.4% in the 10% bound-
aries; 24.5% in the 40% boundaries).
Taking a ﬁrst VL $1000 copies per
milliliter as reference, the positive pre-
dictive value (PPV) increased from 67%
(10% boundaries) to 89% (40% bound-
aries), and the corresponding sensitivity
from 47% to 60%.
Method 2, using a ﬁxed targeted
percentage to receive VL testing, resulted
in larger CD4-value intervals than in the
article of Koller et al. Taking a ﬁrst VL
$1000 copies per milliliter as reference,
the PPV increased from 78% (10% tested)
to 100% (40% tested), and the correspond-
ing sensitivity from 51% to 71%. All the
estimates that we obtained with method 2
fell between the range of values obtained
by Koller et al, or better. If a sustained
virologic failure was taken as a reference
(2 VL $1000 copies per milliliter; $3
months apart), the PPV would decrease by
up to 30%, whereas the sensitivity would
remain stable or slightly increase.
We also tried to include those
patients on ART .5 years as if they
had been on ART for 5 years. This did
not change results substantially: differ-
ences were at maximum of 7%, 6%, and
4%, with, respectively, 10%, 20%, and
40% of VL testing.
In the same patient-cohort WHO-
proposed immunological criteria for
treatment failure2 had a sensitivity of
16% and a PPV of 56% for a single VL
$1000 copies per milliliter and a sensi-
tivity and PPV for sustained virologic
failure of 22% and 50%, respectively.
Several groups elaborated algo-
rithms using clinical and laboratory
information to predict virologic out-
comes among patients on ﬁrst-line
ART. Liu et al9 developed an algorithm
based on CD4 values and simple clinical
markers. Tested in a data set from a US
patient cohort, this approach had high
accuracy in predicting VL $400 copies
per milliliter. It has to our knowledge,
however, not been validated in resource-
limited settings. Evans et al10 developed
a score using a variety of clinical and
laboratory variables at baseline and
follow-up. This score had high accuracy.
It, however, includes laboratory values,
such as mean cell volume and albumin,
which are usually not part of routine
laboratory follow-up in resource-
constrained settings. Based on data from
a cohort on ﬁrst-line ART in Cambodia,
Lynen et al5 developed a clinical pre-
diction score, including CD4 count,
change in hemoglobin, drug adherence,
and presence of papular pruritic erup-
tion. Whereas the score performed well
in Cambodia11 and Lesotho,6 it had very
poor accuracy in Uganda.12 All these
approaches require reliably documented
clinical and laboratory history that may
not implicitly be available in resource-
limited settings. Van Griensven et al13
assessed simpliﬁed scores that do not
require hemoglobin measurement and
no baseline CD4 count. These scores
had a still acceptable accuracy in
a Cambodian cohort.
A strength of the risk charts of
Koller et al is that they only require
a baseline and a current CD4 count.
Poor documentation of additional labo-
ratory values or clinical history is a real-
ity in many resource-limited settings.
Adherence measurement, such as
pill count during pharmacy reﬁll, does not
require speciﬁc equipment, is relatively
cheap, and was predictive of virologic
outcome in several studies.14–16 It was,
however, not associated with virologic
failure in the CART-1 study, the data set
we used for this analysis.17
Implementation of the risk charts
developed by Koller et al would mean
that health care providers possess charts
adapted to their context. At each visit
where patients on ﬁrst-line ART obtain
a CD4 count result, HIV care providers
could check on these charts if the patient
falls into the intermediate risk group and
decide if a VL is indicated. To do so, the
provider only needs 4 variables: sex,
time on ART, CD4 count at baseline,
and current CD4 count. Such a scenario
seems realistic and feasible—even in
very resource-limited settings, such as
Lesotho, where HIV care has been
shifted to nurses. It may be much more
realistic than more complex algorithms
and scores that require technology or
information that may not be available or
adherence measurements that are prone
to interobserver variability.
In conclusion, in this multicenter
cohort from rural Lesotho, the CD4-
risk charts performed at least as well, if
not better, than in the original article of
Koller et al and substantially better
than the WHO criteria for immunolog-
ical failure. Risk charts may be of
particular interest to settings that start
VL testing, but where resources do not
allow routine VL monitoring for all
patients yet. Before implementation at
a larger scale, their accuracy for sus-
tained virologic failure that would
eventually trigger switch to second-
line ART should be further examined.
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